No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
CN Stock MarketDetailed Quotes
002821 Asymchem Laboratories
- 67.90
- -1.45-2.09%
Not Open Jul 23 15:00 CST
25.09BMarket Cap13.06P/E (TTM)
69.58High67.88Low35.24KlotVolume68.72Open69.35Pre Close242.34MTurnover1.07%Turnover Ratio11.06P/E (Static)369.47MShares163.5452wk High1.48P/B22.31BFloat Cap59.8252wk Low76.29Limit Up328.54MShs Float376.25Historical High62.42Limit Down2.45%Amplitude7.48Historical Low1.80Dividend TTM68.77Avg Price19.02KlotAsk2.65%Div YieldTTM100Lot Size14.26KlotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Fund Subscribed by Asymchem Laboratories' Unit Completes Establishment; HK, Shenzhen Shares Up 3%
Hong Kong stocks concept tracking | New signed order amount achieve a double-digit growth CXO expected to recover (including concept stocks)
Since 2024, Asymchem Laboratories has accelerated overseas layout and polypeptide production capacity construction, with new order growth exceeding 20% year-on-year.
Asymchem Laboratories (06821) participated in the investment fund and completed the private equity fund filing.
Asymchem Laboratories (06821) announced that the fourth Board of Directors meeting will be held on April 29, 2024 for the fiftieth time.
Asymchem Laboratories Announces Shareholder Meeting Outcomes
Hong Kong stocks saw unusual activity as CRO concept stocks rose collectively. With the nearing interest rate cut by the Federal Reserve and frequent bullish policies, the sector is expected to usher in marginal improvements.
Concept stocks of CRO have collectively risen. As of press time, Tigermed (03347) rose 4.75%, to HKD 28.65; Genscript Bio (01548) rose 4.66%, to HKD 13.02.
Asymchem Laboratories (Tianjin) Co., Ltd.'s (SZSE:002821) Low P/E No Reason For Excitement
Comments
Asymchem Laboratories (Tianjin)'s low P/E ratio may be due to investors' belief in the company's poor earnings performance. The outlook for shrinking earnings contributes to its low P/E, forming a barrier for the share price.
Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) Stock Catapults 26% Though Its Price And Business Still Lag The MarketAsymchem Laboratories (Tianjin)'s low P/E ratio is due to predicted declining earnings. Investors see limited potential for earnings improvement, hence a higher P/E ratio isn't justified, indicating a stagnant share price.
$Hang Seng Index(800000.HK$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
1
Read more
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
%Chg